To the full analysis
Teleflex stock: growth
TFXTeleflex reported $1.99B in revenue for fiscal 2025, down 34.6% on the prior year, up 6.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−1.5%
per year from 2006 to 2025, per share −2.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
−0.7%
per year from 2006 to 2025, per share −1.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −4.7% | 1.0% | −1.5% |
| Revenue per share | −3.9% | 0.3% | −2.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −6.6% | 0.3% | −0.7% |
| Free cash flow per share | −5.9% | −0.5% | −1.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $2.65B | $139.43M | $281.43M |
| 2007 | $1.93B | $146.48M | $348.85M |
| 2008 | $2.42B | $119.77M | $131.9M |
| 2009 | $1.89B | $302.99M | $173.76M |
| 2010 | $1.8B | $201.09M | $179.57M |
| 2011 | $1.53B | $323.33M | $49.39M |
| 2012 | $1.55B | −$190.06M | $120.66M |
| 2013 | $1.7B | $150.88M | $162.96M |
| 2014 | $1.84B | $187.68M | $218.99M |
| 2015 | $1.81B | $244.86M | $239.36M |
| 2016 | $1.87B | $237.38M | $355.35M |
| 2017 | $2.15B | $152.53M | $348.98M |
| 2018 | $2.45B | $200.8M | $356.58M |
| 2019 | $2.6B | $461.47M | $336.83M |
| 2020 | $2.54B | $335.32M | $345.71M |
| 2021 | $2.81B | $485.37M | $579.8M |
| 2022 | $2.79B | $363.14M | $262.95M |
| 2023 | $2.97B | $356.33M | $419.2M |
| 2024 | $3.05B | $69.68M | $509.31M |
| 2025 | $1.99B | −$905.64M | $245.44M |
Revenue by segment
How Teleflex Incorporated makes its money and how that has shifted. Names are as the company reports them.
- Vascular Access$917.7M46%
- Interventional$647.8M33%
- Surgical$418.2M21%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Vascular Access | $917.73M | 46.1% |
| Interventional | $647.79M | 32.5% |
| Surgical | $418.16M | 21% |
| Total revenue | $1.99B | 100% |
Revenue by region
Where Teleflex Incorporated generates its revenue.
- United States$1.2B59%
- EMEA$484.7M24%
- Asia$218.0M11%
- Other$108.1M5%
“Other” combines smaller regions with revenue the company does not assign to a region. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $1.18B | 59.3% |
| EMEA | $484.73M | 24.3% |
| Asia | $218.03M | 10.9% |
| Other | $108.13M | 5.4% |
| Total revenue | $1.99B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Oct 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.